If the cells you would like to access are currently listed as unavailable or you are ordering from outside of Europe please get in touch via Contact@EBiSC.org.

BIONi010-C-5

BIONi010-C CD33 E2del #N14 P26

Gene-edited iPSC line

Not-for-profit fee: £1700 per vial
Immediately available for distribution*
*Once all legal and processing details completed
A CLIP contains information about a cell line including any specific third party obligations relating to, for example, licensing obligations or the donor consent which affect the use of the cell line.

The EBiSC Access and Use Agreement must be completed along with an individual Cell Line Information Pack for each line. Complete the EAUA and send to Contact@EBiSC.org for countersignature. The EAUA must be fully signed before proceeding with your order.
A batch specific Certificate of Analysis will be available to download once you receive your EBiSC iPSC line.

General#

Cell Line

hPSCreg name BIONi010-C-5
Alternative name(s)
BIONi010-C CD33 E2del #N14 P26
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
BIONi010-C-9
(BIONi010-C CD33 KO)
BIONi010-C-3
(BIONi010-C ApoE KO #KO30 P30)
BIONi010-C-25
(BIONi010-C heterozygous TREM2 KO)
BIONi010-C-17
(BIONi010-C TREM2 KO)
BIONi010-C
(BIONi010-C, K3P53)
BIONi010-C-2
(BIONi010-C ApoE E3/E3 #H8 P32)
BIONi010-C-70
(BIONi010-C with an APOE 2/2 genotype with an additional, homozygous christchurch mutation)
BIONi010-C-71
(BIONi010-C with an APOE 3/3 genotype with an additional, homozygous christchurch mutation)
BIONi010-C-4
(BIONi010-C ApoE E4/E4 #B44 P27)
BIONi010-C-6
(BIONi010-C ApoE E2/E2)
BIONi010-C-7
(BIONi010-C Trem2 R47H)
BIONi010-C-8
(BIONi010-C Trem2 T66M, #Y5-80)
BIONi010-C-13
(BIONi010-C + NGN2 #I7-26)
BIONi010-C-15
(BIONi010-C +dox inducible NGN2-GFP)
BIONi010-C-18
(BIONi010-C TBK1 KO)
BIONi010-C-51
(BIONi010-C TNNI3-mCherry reporter)
BIONi010-C-19
(BIONi010-C IKBKE KO)
BIONi010-C-10
(HNF1AP291fsinsC +/- 54-5)
BIONi010-C-11
(HNF1AP291fsinsC -/- 66-1)
BIONi010-C-12
(HNF4ApR309C -/- 2-4)
BIONi010-C-52
(BIONi010-C with an APOE 2/2 genotype (with two functional alleles in contrast to BIONi010-C-6))
BIONi010-C-53
(BIONi010-C with an APOE 3/3 genotype (with two functional alleles in contrast to BIONi010-C-2))
BIONi010-C-55
(BIONi010-C TNNI3-mCherry/TNNI1-EGFP dual reporter cl. 74)
BIONi010-C-24
(BIONi010-C Dox a-syn)
BIONi010-A
(K1P53)
BIONi010-B
(K2P53, BIONi010-B)
UKBi011-A-3
(ApoE 3/3)
Donor's gene variants:
APOE, APOE
Donor diseases:
Alzheimer disease
UKBi011-A-4
(ApoE 3/4)
Donor's gene variants:
APOE, APOE
Donor diseases:
Alzheimer disease
Notes No larger chromosomal aberrations to be reported. Chr22: 1,4Mbp duplication in q11.23

Provider

Depositor Bioneer (BION)
Distributors
EBiSC
Derivation country Denmark

External Databases

hPSCreg BIONi010-C-5
BioSamples SAMEA4452061
Cellosaurus CVCL_II84
Wikidata Q54796776

General Information

Publications View all related publications on hPSCreg (2)
This EBiSC line can be used for:
Yes
Research use: allowed
Clinical use: no
Commercial use: no
Subclone of

Donor Information#

General Donor Information

Sex male
Ethnicity Black or African-American

Phenotype and Disease related information (Donor)

Diseases No disease was diagnosed.

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

Donor Relations

Other cell lines of this donor

External Databases (Donor)

BioSamples SAMEA3105780

hIPSC Derivation#

General

The source cell information can be found in the parental cell line BIONi010-C.

Reprogramming method

Vector type Non-integrating
Vector Episomal
Genes
Is reprogramming vector detectable?
No

Vector free reprogramming

Other

Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions#

The following are the depositor culture conditions, they do not refer to any specific batch.
Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzyme-free cell dissociation
EDTA
O2 Concentration 18 %
CO2 Concentration 5 %
Medium Essential 8™
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
No

Characterisation#

Analysis of Undifferentiated Cells
Morphology pictures
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro directed differentiation
Marker Expressed
CXCR4
Yes
GATA6
Yes
FOXA2
Yes
SOX17
Yes
GSC
Yes
Mesoderm
Ont Id: UBERON_0000926
In vitro spontaneous differentiation
Marker Expressed
Vimentin
Yes
DCN
Yes
Ectoderm
Ont Id: UBERON_0000924
In vitro spontaneous differentiation
Marker Expressed
PAX6
Yes
NEUROD1
Yes
HES5
Yes

Microbiology / Virus Screening

HIV 1 Negative
HIV 2 Negative
Hepatitis B Negative
Hepatitis C Negative
Mycoplasma Negative

Sterility

Inoculation for microbiological growth No Contaminants Detected
Mycoplasma Not Detected
Viability Viable post-cryopreservation

Genotyping#

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46 XY
Passage number: 27

Other Genotyping (Cell Line)

Is there genome-wide genotyping or functional data available?
Yes
Whole genome sequencing
https://ega-archive.org/studies/EGAS00001002755
This cell line has undergone WGS using the Illumina HiSeq X platform at 30x coverage. Fastq files are stored at the European Genome Archive, users can apply for access to this data by submitting an application form to the EBiSC Data Access Committee https://ega-archive.org/dacs/EGAC00001000768

Genetic Modification#

Disease/phenotype related modifications
Synonyms
  • AD
  • Alzheimer dementia
  • Alzheimer disease
  • Alzheimer's dementia
  • Alzheimer's disease
  • Alzheimers dementia
  • Alzheimers disease
  • presenile and senile dementia
  • Alzheimer disease, familial
show more synonyms
Genetic modifications
CD33 (target)
Isogenic modification
19q13.41
Homozygous
Exon2 of the CD33 gene has been cut out by CRISPR technology
Exon2 of the CD33 gene has been cut out by CRISPR technology